Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Shaoyan New Drug Shareholder Gu Xiaolei and Concerted Parties Plan to Reduce Holdings of 30.7425 Million Shares, Accounting for 4.10% of Total Share Capital
Log in to Sina Finance App and search for [Disclosure of Information] to see more evaluation levels.
Beijing Zhaoyan New Drug Research Center Co., Ltd. (hereinafter referred to as “Zhaoyan New Drug”) announced on March 17, 2026, a shareholder reduction plan. Shareholders Gu Xiaolei and his concerted action partner Gu Meifang plan to reduce a total of 30,742,500 shares through centralized bidding within the next three months, accounting for 4.1026% of the company’s current total share capital.
Shareholder Holdings Overview
The announcement shows that Gu Xiaolei and Gu Meifang are concerted action partners and are related as uncle and niece. As of the disclosure date, Gu Xiaolei holds 20,420,504 A-shares, representing 2.7251%; Gu Meifang holds 10,322,035 A-shares, representing 1.3775%. Together, they hold 30,742,500 shares, accounting for 4.1026% of the total share capital.
Details of the Reduction Plan
According to the announcement, Gu Xiaolei and his concerted action partner Gu Meifang plan to reduce their holdings via Shanghai Stock Exchange’s centralized bidding method over a period of three months starting three trading days after the announcement (from March 20, 2026, to June 19, 2026). Gu Xiaolei plans to reduce 20,420,504 shares, representing 2.7251% of the total share capital; Gu Meifang plans to reduce 10,322,035 shares, representing 1.3775%.
The announcement states that the reduction price will be determined based on market prices. If the company undergoes share capital adjustments such as dividend shares, capital increases, or rights issues during the reduction period, the reduction amount will be adjusted accordingly.
Risk Warning and Impact
Zhaoyan New Drug emphasizes in the announcement that Gu Xiaolei and Gu Meifang are not controlling shareholders or actual controllers of the company. The implementation of this share reduction plan will not lead to a change in the company’s control or significantly impact corporate governance and ongoing operations. Additionally, the two shareholders will consider market conditions, stock prices, and other factors when deciding the reduction amount and price, and there is uncertainty whether they will fully reduce their holdings.
The company states that it will continue to monitor the reduction activities of relevant shareholders during the implementation period and fulfill information disclosure obligations promptly. Investors should be aware of the potential market risks associated with this reduction plan.
Disclaimer: The market carries risks; investments should be cautious. This article is automatically published by an AI large model based on third-party databases and does not represent Sina Finance’s views. All information herein is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for accuracy. If you have any questions, contact biz@staff.sina.com.cn.
Click here to view the original announcement>>
Massive information, precise interpretation, all on Sina Finance App.
Editor: Xiao Lang Kuai Bao